DICE Therapeutics
Venkat joined DICE Therapeutics in June 2021 as the Senior Vice President of CMC. Prior to DICE, Venkat was at Theravance Biopharma for 12 years, most recently serving as the Vice President and Head of Pharmaceutical Development. At Theravance, Venkat contributed to 15 research and development programs ranging from preclinical to Phase 3 clinical products as well as the marketed products YUPELRI® and VIBATIV®. Venkat led multiple drug product development programs at Theravance, most recently ampreloxitine for symptomatic neurogenic orthostatic hypotension, izencitinib for ulcerative colitis and Crohn’s disease, nezulcitinib for COVID-19, TD-8236 for asthma, and TD-1058 for idiopathic pulmonary fibrosis. These programs included tablets for oral delivery to nebulized solutions and inhaled dry powders for lung delivery. Venkat ushered in new drug delivery technologies at Theravance, leading the efforts in an ocular program to develop products that last in the eye for several months and a topical program that resulted in partnership with Pfizer.
Prior to Theravance, Venkat was at XenoPort as a Principal Investigator in the formulation development group and at Worcester Polytechnic Institute as an Assistant Professor in the Department of Chemistry and Biochemistry. Venkat received his PhD in Chemistry from the University of Hyderabad and conducted post-doctoral work at the University of Essen and Harvard University.
This person is not in any offices
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.